earnings
confidence high
sentiment neutral
materiality 0.75
Organon FY21 rev $6.3B, adj. EPS $6.54; provides FY22 guide rev $6.1-$6.4B, adj. EBITDA margin 34-36%
Organon & Co.
2021-FY EPS reported
$5.31
revenue$6,304,000,000
- FY21 revenue $6.3B (-3% as-reported vs 2020); GAAP diluted EPS $5.31; non-GAAP adj. diluted EPS $6.54.
- Q4 revenue $1.604B (-1% YoY); adj. EBITDA margin 34.2% vs 42.2% in prior year.
- Board declared $0.28 quarterly dividend payable March 17, 2022; record date Feb 28.
- FY22 guidance: revenue $6.1-$6.4B; adj. EBITDA margin 34%-36%; interest ~$400M; tax rate 17.5%-19.5%.
- Growth engines (Nexplanon, fertility, biosimilars) grew double digits; 4 business development deals since spin.